Annovis Bio develops buntanetap, an experimental oral drug for Alzheimer's and Parkinson's disease. It last closed at $0.75 on Nov 17, down 2.44% on the day.
Only 1 firm rated ANVS in the past 90 days, not enough for a consensus
Average 12-month target
$3.00
▲ 302.0% upside
Based on 1 analyst who set a price target on ANVS in the past 90 days. The average target is $3.00, with a high of $3.00 and a low of $3.00, compared with the last close of $0.75.
Low $3.00Avg $3.00High $3.00
Blue marker: last close $0.75
Highest target$3.00
Average target$3.00
Lowest target$3.00
Latest rating changes
Roth CapitalTarget lowered
Nov 16Buy$7 → $3
Roth CapitalTarget lowered
Aug 28Buy$8 → $7
Canaccord GenuityMaintained
Aug 18Buy$17
Roth CapitalInitiated
Jul 8Buy$8
Date
Firm
Action
Rating
Price target
Nov 16
Roth Capital
Target lowered
Buy
$7 → $3
Aug 28
Roth Capital
Target lowered
Buy
$8 → $7
Aug 18
Canaccord Genuity
Maintained
Buy
$17
Jul 8
Roth Capital
Initiated
Buy
$8
Loading…
Technical Analysis
ANVS · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold
The stock is 27% below its 20 day and 44% below its 50 day average. It is 141% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 38), near oversold. The nearest support is the Pivot S1 at $0.69, and the nearest resistance the Pivot at $0.76.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 17.8%/day
Key levels
$5.5052 week high+633.3%
$1.79200 day average+138.7%
$1.42100 day average+89.3%
$1.0850 day average+44.0%
$1.05Swing high (Oct 22)+40.0%
$0.9520 day average+26.7%
$0.81Pivot R1+8.0%
$0.76Pivot+1.3%
$0.75Last close
$0.69Pivot S1−8.0%
$0.6252 week low−17.3%
$0.62Swing low (Nov 5)−17.3%
Indicators
RSI (14)
37.80
Weak, oversold below 30
Neutral
MACD
-0.09
Below its signal line
Bearish
Stochastic
25.0
Middle of its range
Neutral
ADX (14)
20.4
Weak trend
Williams %R
-83.3
Oversold below −80, overbought above −20
Oversold
CCI (20)
-114.7
Oversold below −100, overbought above 100
Oversold
Rate of change
−32.8%
Change over 10 sessions
Bearish
ATR (14)
$0.13
Typical daily range, 17.8% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, nearing oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 40.2%/day
Key levels
$5.5052 week high+633.3%
$1.79200 day average+138.7%
$1.42100 day average+89.3%
$1.0850 day average+44.0%
$1.05Swing high (Oct 22)+40.0%
$0.9520 day average+26.7%
$0.81Pivot R1+8.0%
$0.76Pivot+1.3%
$0.75Last close
$0.69Pivot S1−8.0%
$0.6252 week low−17.3%
$0.62Swing low (Nov 5)−17.3%
Indicators
RSI (14)
32.60
Weak, oversold below 30
Neutral
MACD
-0.32
Below its signal line
Bearish
Stochastic
16.4
Near the bottom of its range
Oversold
ADX (14)
16.1
No clear trend
Williams %R
-89.9
Oversold below −80, overbought above −20
Oversold
CCI (20)
-116.5
Oversold below −100, overbought above 100
Oversold
Rate of change
−33.4%
Change over 10 sessions
Bearish
ATR (14)
$0.30
Typical daily range, 40.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for ANVS
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how ANVS did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow ANVS usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How ANVS has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ANVS is in one of them and how their past ANVS trades turned out.
Annovis Bio is a drug development company focused on neurodegenerative diseases such as Alzheimer's and Parkinson's. Its main product candidate, buntanetap, is an oral small molecule drug designed to lower several harmful proteins linked to nerve cell damage. The company is still in clinical testing and does not yet have an approved product for sale, so its intended customers are patients with these diseases. It is based in Malvern, Pennsylvania.